Grifols Slows Alzheimer’s Progression With Plasmapheresis
Executive Summary
Plasmapheresis with Grifols’ Albutein could provide a new treatment avenue for Alzheimer’s disease, but more data will be needed to convince.
You may also be interested in...
Moderna Wins Bivalent COVID-19 Vaccine Booster Race With First Approval
Moderna takes the next step in the in the development of COVID-19 vaccines, with the first approval of the first bivalent vaccine that can produce a broader immune response to new SARS-CoV-2 variants.
New Era For Schizophrenia Therapy Beckons As Karuna Soars On Promising Phase III Data
The PureTech Health-founded entity believes it has made a significant step forward in the treatment of schizophrenia with its muscarinic-receptor acting agent KarXT, which could offer a completely new way to address all three symptom domains of the disease.
AZ’s Susan Galbraith On What’s Next In The Cancer Pipeline
One of the architects of AstraZeneca’s burgeoning cancer portfolio, oncology R&D head Susan Galbraith is making sure the firm does not rest on its laurels. She talked to In Vivo about what’s coming next from the UK major’s cancer pipeline.